Marvel obtains Alberta funding for MB-204 phase I

Executive Summary

• Marvel Biosciences Corp. secured $600,000 in non-dilutive funding from the Alberta Innovates CarE (AICE) market access program to support Phase I clinical testing of its lead compound, MB-204.
• The funding provides third-party validation of the scientific and commercial potential of MB-204, a novel treatment for autism spectrum disorders (ASD) and related conditions.
• The company also recently received a grant from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) for the development of a pediatric-friendly, liquid-based formulation of MB-204.

Key Details

• Funding Amount: $600,000 CAD.
• Funding Source: Alberta Innovates CarE (AICE) market access program.
• Purpose of Funds: To support the overall cost of the Phase I clinical trial of MB-204 and advance the program into human trials.
• Validation: The AICE program is described as highly competitive and subject to rigorous peer review, serving as third-party validation of MB-204's potential.
• Additional Grant: Received a separate grant from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP).
• NRC IRAP Purpose: Development of a novel, small volume, liquid-based formulation of MB-204 designed to be pediatric-friendly and improve patient compliance for individuals with difficulty swallowing.
• Target Indication: Autism spectrum disorders (ASD) and related conditions, specifically addressing sociobehavioural symptoms.
• Mechanism of Action: MB-204 is a novel fluorinated derivative of Istradefylline (an approved Parkinson's drug) and is an adenosine A2A receptor blocker.
• Other Potential Indications: Depression, Alzheimer's disease, Rett syndrome, and Fragile X syndrome.
• Company Status: Transitioning from preclinical innovation to clinical-stage execution.

Notable Quotes

• "On behalf of Marvel Biosciences, we are very grateful to Alberta Innovates for recognizing the importance and potential of MB-204 as a novel approach to treating autism spectrum disorders (ASD) and related conditions... This competitive, peer-reviewed funding reinforces growing confidence around MB-204, and its potential to address sociobehavioural symptoms through a differentiated mechanism." — Rod Matheson, Chief Executive Officer